Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert J Rounbehler

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Plos One|December 27, 2014
CREB targets define the gene expression signature of malignancies having reduced levels of the tumor suppressor tristetraprolinMohammad Fallahi, Antonio L Amelio, John L Cleveland, et al.
Cancer Research|May 31, 2002
Inactivation of E2f1 enhances tumorigenesis in a Myc transgenic modelRobert J Rounbehler, Pamela M Rogers, Claudio J Conti, et al.
Molecular Carcinogenesis|October 3, 2009
E2F2 suppresses Myc-induced proliferation and tumorigenesisRaju V Pusapati, Regina L Weaks, Robert J Rounbehler, et al.
Cancer Research|January 17, 2009
Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastomaRobert J Rounbehler, Weimin Li, Mark A Hall, et al.
Methods in Molecular Biology (Clifton, N.J.)|September 14, 2020
Accessible Pipeline for Translational Research Using TCGA: Examples of Relating Gene Mechanism to Disease-Specific OutcomesAnders E Berglund, Ryan M Putney, Jordan H Creed, et al.
Molecular and Cellular Biology|February 13, 2002
ARF differentially modulates apoptosis induced by E2F1 and MycJamie L Russell, John T Powers, Robert J Rounbehler, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 24, 2019
Commercial Gene Expression Tests for Prostate Cancer Prognosis Provide Paradoxical Estimates of Race-Specific RiskJordan H Creed, Anders E Berglund, Robert J Rounbehler, et al.
Oncotarget|November 9, 2016
Tristetraprolin disables prostate cancer maintenance by impairing proliferation and metabolic functionAnders E Berglund, Kristen E N Scott, Weimin Li, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 25, 2006
ATM promotes apoptosis and suppresses tumorigenesis in response to MycRaju V Pusapati, Robert J Rounbehler, SungKi Hong, et al.
Cell|August 7, 2012
Tristetraprolin impairs myc-induced lymphoma and abolishes the malignant stateRobert J Rounbehler, Mohammad Fallahi, Chunying Yang, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Plos One|December 27, 2014
CREB targets define the gene expression signature of malignancies having reduced levels of the tumor suppressor tristetraprolinMohammad Fallahi, Antonio L Amelio, John L Cleveland, et al.
Cancer Research|May 31, 2002
Inactivation of E2f1 enhances tumorigenesis in a Myc transgenic modelRobert J Rounbehler, Pamela M Rogers, Claudio J Conti, et al.
Molecular Carcinogenesis|October 3, 2009
E2F2 suppresses Myc-induced proliferation and tumorigenesisRaju V Pusapati, Regina L Weaks, Robert J Rounbehler, et al.
Cancer Research|January 17, 2009
Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastomaRobert J Rounbehler, Weimin Li, Mark A Hall, et al.
Methods in Molecular Biology (Clifton, N.J.)|September 14, 2020
Accessible Pipeline for Translational Research Using TCGA: Examples of Relating Gene Mechanism to Disease-Specific OutcomesAnders E Berglund, Ryan M Putney, Jordan H Creed, et al.
Molecular and Cellular Biology|February 13, 2002
ARF differentially modulates apoptosis induced by E2F1 and MycJamie L Russell, John T Powers, Robert J Rounbehler, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 24, 2019
Commercial Gene Expression Tests for Prostate Cancer Prognosis Provide Paradoxical Estimates of Race-Specific RiskJordan H Creed, Anders E Berglund, Robert J Rounbehler, et al.
Oncotarget|November 9, 2016
Tristetraprolin disables prostate cancer maintenance by impairing proliferation and metabolic functionAnders E Berglund, Kristen E N Scott, Weimin Li, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 25, 2006
ATM promotes apoptosis and suppresses tumorigenesis in response to MycRaju V Pusapati, Robert J Rounbehler, SungKi Hong, et al.
Cell|August 7, 2012
Tristetraprolin impairs myc-induced lymphoma and abolishes the malignant stateRobert J Rounbehler, Mohammad Fallahi, Chunying Yang, et al.
Pageof 4